GE HealthCare stock maintained at Buy by BTIG on imaging tech
BTIG maintained a Buy rating and $79 price target for GE HealthCare (GEHC) after positive feedback on its new photon-counting CT system. GEHC stock is down 22% YTD but is considered undervalued. The company reported Q2 revenue of $5.295B, beating estimates, and raised its price target to $85. GEHC's backlog reached $23.9B, indicating strong demand.
How this was made
The 30-second read
Why it matters
The combined earnings beat and FDA clearance create a compelling short‑term catalyst for the stock.
Market read
Strong earnings and a new product clearance could drive GEHC higher, influencing the broader healthcare equipment sector.
What to watch
Potential reimbursement challenges for photon-counting CT could temper upside.
Background
The article combines BTIG analyst commentary with recent Q2 earnings and regulatory updates for GE HealthCare.
Ticker impact
GE HealthCare reported Q2 revenue beat estimates and received FDA clearance for its Photonova Spectra CT system, prompting BTIG to raise its price target.
Potential upside of 10-15% over the next few weeks if guidance holds.
Earnings beat, strong order growth, and first US clearance for a premium CT system provide clear upside catalysts.
Market effects
Healthcare equipment sector may see renewed interest in advanced imaging technologies.
U.S. medical device market gains confidence from FDA clearance.
Competitors like Siemens may face pressure as GEHC secures first U.S. clearance.
Counterpoint
If Siemens' system issues persist, GEHC's premium pricing could limit adoption.
Key entities
- companyGE HealthCare
U.S.-listed medical imaging equipment maker.
- analyst_firmBTIG
Equity research firm that raised its price target.
